ŌURA Partners with LillyDirect to Boost GLP-1 Therapy Support
Event summary
- ŌURA and LillyDirect collaborate to offer free Oura Ring sizing kits to LillyDirect customers.
- The partnership aims to improve access to GLP-1 therapies and integrated behavioral support tools.
- Over half of ŌURA members identify as having obesity or being overweight, with tens of thousands already tracking GLP-1 therapy use in the app.
- ŌURA introduced GLP-1 Insights last month, a companion experience designed to support people using GLP-1 therapy.
The big picture
This collaboration underscores the growing trend of pharmaceutical companies partnering with digital health platforms to create more comprehensive care ecosystems. The integration of biometric tracking with GLP-1 therapies highlights a strategic shift towards personalized, data-driven healthcare solutions. With global adoption of GLP-1 therapies expected to surge, this partnership positions both ŌURA and LillyDirect at the forefront of chronic condition management.
What we're watching
- Market Expansion
- The pace at which GLP-1 therapy adoption grows globally, projected to exceed 100 million people by 2030.
- Integration Success
- How effectively ŌURA and LillyDirect can integrate biometric data with GLP-1-specific context for holistic health support.
- Competitive Dynamics
- Whether this partnership will spur similar collaborations between pharma companies and digital health platforms.
Related topics